New cancer drug SPGL008 enters first human tests
NCT ID NCT07038005
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new biologic drug called SPGL008 in 96 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. The drug is given either through a vein or under the skin. This is a Phase 1 study, so it is too early to know if the drug works against cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPGL008 (a biologic drug)
What this could lead to
If safe and effective, SPGL008 could become a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, not on curing cancer. Many drugs fail at this stage, and side effects are unknown. Results may not apply to all cancer types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
RECRUITINGChongqing, Chongqing Municipality, 400030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••